# Psychedelic-Assisted Psychotherapy: Psilocybin and MDMA

## Introduction

**Psychedelic-assisted psychotherapy (PAP)** represents one of the most significant developments in psychiatric treatment in decades. After a decades-long regulatory hiatus, rigorous clinical trials have demonstrated the therapeutic potential of **psilocybin** for treatment-resistant depression and end-of-life distress, and **MDMA** for post-traumatic stress disorder. This lecture reviews the pharmacology, clinical evidence, therapeutic frameworks, and ethical considerations surrounding this emerging field.

## Historical Context

Psychedelic research flourished in the 1950s-1960s with over 1,000 published studies on LSD and psilocybin. Research was halted by the Controlled Substances Act of 1970, which classified these compounds as **Schedule I** (no accepted medical use, high abuse potential) The modern renaissance began in the 2000s, led by Johns Hopkins, NYU, and MAPS (Multidisciplinary Association for Psychedelic Studies) FDA designated psilocybin as a **Breakthrough Therapy** for treatment-resistant depression (2018) and MDD (2019) MDMA-assisted therapy received Breakthrough Therapy designation for PTSD (2017)

## Psilocybin

### Pharmacology

**Prodrug** converted to psilocin, which is a potent **5-HT2A receptor agonist**. Also activates 5-HT2C, 5-HT1A, and other serotonin receptors. Onset: 20-40 minutes; peak effects: 60-90 minutes; duration: 4-6 hours. Subjective effects: altered perception, synesthesia, emotional intensification, ego dissolution, mystical-type experiences. Neurobiologically: reduces **default mode network (DMN) activity**, increases functional connectivity between normally segregated brain networks, and promotes **neuroplasticity via BDNF/TrkB signaling**.

### Clinical Evidence

#### Treatment-Resistant Depression

Carhart-Harris et al. (2021): psilocybin (25 mg) showed rapid and sustained antidepressant effects comparable to escitalopram over 6 weeks in an open-label comparison. Multiple RCTs demonstrate significant reductions in depression severity with effect sizes exceeding those of conventional antidepressants.

#### End-of-Life Distress

Griffiths et al. (2016): single high-dose psilocybin produced rapid, sustained reductions in anxiety and depression in patients with life-threatening cancer diagnoses. Ross et al. (2016): similar findings at NYU; approximately 80% of participants showed clinically significant decreases in distress at 6-month follow-up. Effects mediated by the quality of the **mystical experience** during the session.

#### Major Depressive Disorder

COMPASS Pathways Phase IIb trial: psilocybin 25 mg demonstrated significant antidepressant effects vs. 1 mg (control dose) at 3 weeks. Ongoing Phase III trials.

![Summary of key psilocybin clinical trials and outcomes](images/psilocybin-clinical-trials.png)

## Comparison: Psilocybin vs. MDMA

| Feature | Psilocybin | MDMA |
|---------|-----------|------|
| Drug class | Classic psychedelic (tryptamine) | Empathogen/entactogen |
| Primary mechanism | 5-HT2A agonism | Serotonin/dopamine/NE release; oxytocin increase |
| Onset / Duration | 20-40 min / 4-6 hours | 30-60 min / 3-5 hours |
| Subjective effects | Altered perception, ego dissolution, mystical experiences | Empathy, emotional openness, reduced fear |
| Primary indication studied | Treatment-resistant depression; end-of-life distress; MDD | PTSD |
| Key efficacy data | ~50-70% response in TRD; 80% reduced distress in cancer patients | 67% no longer met PTSD criteria at 18 months |
| Sessions in protocol | 1-2 medicine sessions | 3 medicine sessions (8 hr each) |
| Hallucinations | Yes (visual, perceptual) | No (typically) |
| Neurotoxicity concern | Minimal at clinical doses | Serotonergic neurotoxicity at high repeated doses |
| FDA status | Breakthrough Therapy designation (2018/2019) | Breakthrough Therapy designation (2017); advisory review 2024 |

## MDMA

### Pharmacology

**3,4-methylenedioxymethamphetamine**: an empathogen/entactogen. Mechanism: releases **serotonin, dopamine, and norepinephrine** from presynaptic terminals; increases oxytocin and prolactin. Onset: 30-60 minutes; peak: 75-120 minutes; duration: 3-5 hours. Subjective effects: increased empathy, emotional openness, reduced fear and defensiveness, enhanced introspection, prosocial feelings. Unlike classic psychedelics, MDMA does not typically produce visual hallucinations or ego dissolution.

### Clinical Evidence for PTSD

MAPS-sponsored Phase III trials (Mithoefer et al., Mitchell et al.) MDMA-assisted therapy: 3 preparation sessions, 3 MDMA sessions (8 hours each), and 9 integration sessions. Results: **67% of participants no longer met PTSD criteria** at 18-month follow-up (compared to 32% with therapy alone) Effect sizes were large (Cohen's d approximately 0.9) Effective in treatment-resistant PTSD, including military veterans and survivors of sexual assault. FDA Advisory Committee review occurred in 2024; regulatory pathway continues to evolve.

### Safety Profile

Acute effects: elevated heart rate and blood pressure, jaw clenching (bruxism), hyperthermia, nausea. Neurotoxicity concerns: high-dose, repeated recreational use has been associated with serotonergic neurotoxicity in animal studies; clinical protocol doses (3 sessions) have not demonstrated lasting harm. Cardiovascular screening is recommended; contraindicated in uncontrolled hypertension. Abuse potential exists in recreational contexts but is managed in clinical settings through supervised administration.

## The Therapeutic Framework

### Key Principles

PAP is not simply administering a drug; it is a **psychotherapy-augmented-by-pharmacology model**:
**Preparation sessions**: establish therapeutic alliance, set intentions, discuss expectations, provide psychoeducation about the drug experience. **Medicine session**: the patient ingests the compound in a carefully prepared setting with trained therapists present throughout; music playlists are used to guide the experience; therapists provide support but allow the patient's internal experience to unfold. **Integration sessions**: process the experience, extract meaning, connect insights to therapeutic goals, consolidate changes.

### Set and Setting

**Set**: the patient's mindset, expectations, psychological readiness. **Setting**: the physical environment (comfortable, calm, dimly lit) and interpersonal context (trusting therapeutic relationship) Both profoundly influence the quality and safety of the experience.

### Therapist Training

Specialized training is required; conventional psychiatric or psychotherapy training is necessary but not sufficient. Training includes personal experience with the compound (in some programs), supervision, and adherence to treatment manuals. Ethical standards are critical given the heightened vulnerability of patients during altered states.

![Structure of the psychedelic-assisted psychotherapy treatment model](images/pap-treatment-structure.png)

## Proposed Mechanisms of Action

### Neurobiological

**Enhanced neuroplasticity**: increased BDNF, dendritic growth, and synaptic connectivity. **DMN disruption**: temporary dissolution of rigid self-referential processing allows new perspectives. **Increased functional connectivity**: communication between normally segregated brain regions. **Amygdala modulation**: reduced fear response (MDMA), altered emotional processing (psilocybin)

### Psychological

**Emotional breakthrough**: access to and processing of previously avoided emotions and memories. **Mystical/peak experiences**: associated with enduring positive changes in attitudes, mood, and behavior. **Increased psychological flexibility**: reduced cognitive rigidity and rumination. **Connectedness**: enhanced sense of connection to self, others, and the world.

## Safety Considerations and Contraindications

### Contraindications

Personal or family history of **psychotic disorders** (psilocybin): risk of precipitating psychosis. Uncontrolled cardiovascular disease (MDMA) Current use of SSRIs or MAOIs (drug interactions; serotonin syndrome risk with MDMA; SSRIs may attenuate psilocybin effects) Active suicidality without appropriate clinical infrastructure. Pregnancy.

### Challenging Experiences

"Bad trips" (anxiety, paranoia, frightening imagery) occur and are managed with psychological support, not pharmacological intervention whenever possible. Benzodiazepines may be used as rescue medication if the experience becomes unmanageable. Challenging experiences can be therapeutically valuable when properly integrated.

### Ethical Concerns

**Power dynamics**: patients in altered states are highly suggestible and vulnerable; boundary violations are a serious risk. Reports of sexual abuse by therapists in underground psychedelic therapy settings. Robust ethical frameworks, dual-therapist models, and video recording of sessions are essential safeguards. **Equity and access**: current trial participation is disproportionately white and affluent; ensuring equitable access is a priority. Indigenous cultural considerations: many psychedelic compounds have deep roots in indigenous practices; reciprocity and respect are essential.

![Safety considerations and contraindications for psychedelic-assisted psychotherapy](images/pap-safety-considerations.png)

## Key Clinical Pearls

Psychedelic-assisted psychotherapy is not microdosing or recreational use; it is a structured therapeutic intervention. The therapeutic relationship and integration sessions are as important as the compound itself. Psilocybin's rapid antidepressant effects and durability challenge the paradigm of daily medication for depression. MDMA-assisted therapy has produced the largest effect sizes ever observed in PTSD clinical trials. The field is evolving rapidly; stay current with FDA decisions, emerging evidence, and ethical guidelines. These treatments are not yet widely available outside of clinical trials and approved programs; premature adoption without proper training and infrastructure is dangerous.

## References

1. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. *N Engl J Med*. 2021;384(15):1402-1411.
2. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. *Nat Med*. 2021;27(6):1025-1033.
3. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *J Psychopharmacol*. 2016;30(12):1181-1197.
4. Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. *Pharmacol Ther*. 2019;197:83-102.